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Oxaliplatin is a third‑generation, platinum‑based antitumor drug used to treat colorectal cancer. Since its main adverse effect is 
neuropathic pain resulting from chemotherapy‑induced peripheral neuropathy (CIPN), this drug is used to study the neurobiology 
of CIPN in rodents and to search for analgesics that could attenuate neuropathic pain symptoms – cold and tactile allodynia that 
develop in most of the oxaliplatin‑treated subjects. In this research, testing across various temperatures, we assessed the cold 
reactivity threshold of albino Swiss mice treated with oxaliplatin. We also investigated if amitriptyline, a tricyclic antidepressant drug 
and a sodium channel inhibitor, could attenuate cold allodynia caused by this chemotherapeutic drug. Cold allodynia was induced 
using a  single intraperitoneal dose of oxaliplatin. In the cold plate test while testing various temperatures the pain sensitivity 
threshold was assessed at different time‑points after oxaliplatin (late‑phase allodynia). Antiallodynic activity of intraperitoneal 
amitriptyline was assessed for doses of 1, 2.5 and 10 mg/kg. A statistically significant decrease in latency time to pain reaction was 
detected for all temperatures applied, but the earliest response (i.e., 2 h post‑injection) was noted at 2.5°C. In all experimental 
groups early‑phase cold allodynia was fully developed 3 h after oxaliplatin injection and it was maintained until the end of the 
observation period (7 days). Early‑phase cold allodynia induced by oxaliplatin can be effectively attenuated by amitriptyline. 
Key words: oxaliplatin, amitriptyline, chemotherapy‑induced peripheral neuropathy, neuropathic pain, cold allodynia, cold plate 
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INTRODUCTION
The Neuropathic Pain Special Interest Group (Ne‑
uPSIG) of the International Association for the Study of 
Pain (IASP) defines neuropathic pain as pain caused by 
a lesion or disease that affects somatosensory nervous 
system (Parisi et al. 2017). This type of pain is regarded 
as a chronic disease that has a substantially negative 
effect on patients’ quality of life and is associated with 
high socioeconomic burden (Finnerup et al. 2015). 
Despite a large variety of causes that comprise met‑
abolic, traumatic or iatrogenic factors, including those 
related to adverse drug reactions, neuropathic pain is 
now considered to be a distinct clinical entity (Jensen 
and Finnerup 2014, Manji 2013). Available meta‑analy‑
ses reporting the incidence of adverse drug reactions 
in patients revealed that drug‑induced neuropathies 
are rare and unlikely to be fatal, with the incidence be‑
tween 2 and 4% (Manji 2013, Vilholm et al. 2014), most 
often being manifested as mild sensory paresthesias 
not requiring specific treatment. However, it should be 
noted that if drug‑related neuropathies are associated 
with pain, specific treatment with analgesic drugs is 
usually required (Manji 2013). 
The number of drugs for which drug‑induced neu‑
ropathic pain episodes have been reported is still in‑
creasing (Vilholm et al. 2014). Among these drugs are 
anti‑tumor drugs: platinum‑based drugs, vincristine, 
paclitaxel, thalidomide and bortezomib which are all 
frequently reported to induce severe pain and other in‑
tolerable symptoms of chemotherapy‑induced periph‑
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eral neuropathy (CIPN). Of note, although numerous 
analgesic drugs are currently used to treat neuropathic 
pain of various origins, including CIPN‑related pain, it 
is estimated that about 30‑40% of patients are pharma‑
coresistant to available treatment options (Finnerup 
et al. 2005, Gagnon et al. 2003) and the treatment of 
CIPN remains largely ineffective (Torrance et al. 2013). 
As a consequence, this may lead to chemotherapeutic 
drug dose reduction, or even treatment discontinua‑
tion (Han and Smith 2013). 
Oxaliplatin is a third‑generation platinum‑based 
anti‑tumor drug used to treat advanced colorectal can‑
cer. Compared to other platinum‑based drugs, it has 
a better safety profile featuring a lower incidence of 
hematological adverse effects and reduced gastrointes‑
tinal toxicity. However, it has been demonstrated that 
in approximately 95% of patients oxaliplatin causes 
CIPN and severe neuropathic pain episodes which are 
due to toxic effects of this drug and/or its metabo‑
lite—oxalate, on the somatosensory system and nerve 
hyperexcitability (Ewertz et al. 2015, Manji 2013, Saku‑
rai et al. 2009). Hence, apart from its broad application 
in human and veterinary oncology, oxaliplatin is also 
used under experimental conditions to induce a rodent 
model of CIPN that could be utilized in the search for 
novel analgesics for neuropathic pain. 
Oxaliplatin‑induced CIPN‑related neuropathic pain 
is characterized by a lowered mechanical and thermal 
nociceptive threshold, i.e., tactile allodynia and ther‑
mal (cold) allodynia, respectively. To assess the effect 
of oxaliplatin on tactile allodynia von Frey filaments 
are used in laboratories worldwide. In contrast to this, 
the plethora of methodological differences in protocols 
used for the assessment of oxaliplatin‑induced cold al‑
lodynia in rodents is striking. Researchers use distinct 
temperatures ranging from 0°C (Pevida et al. 2013), 
through 2°C (Mika et al. 2007, Nakanishi et al. 2016), 4°C 
(Berrocoso et al. 2011, Hache et al. 2015, Masocha and 
Parvathy 2016) to 5°C (Sambasevam et al. 2017, Zhao et 
al. 2012), different time‑points at which they assess ani‑
mals’ nociceptive threshold—from 2 h (Zhao et al. 2012) 
to 7 days after oxaliplatin injection (Hache et al. 2015, 
Zhao et al. 2012), and distinct behavioral measures are 
taken as end‑points, i.e., paw withdrawal latencies (e.g, 
paw licking, paw shaking) (Pevida et al. 2013), jumping 
behavior (Hache et al. 2015), or paw lifting (Mika et al. 
2007), and escape behaviors are graded with a score 
from no response to vigorous activity (i.e., jumping) 
(Zhao et al. 2012) or by the duration of the nocifensive 
response (Nakanishi et al. 2016). 
In the light of these methodological differences, it is 
difficult to analyze and compare the analgesic efficacy 
of drugs used for the attenuation of oxaliplatin‑induced 
neuropathic pain. Hence, in the present study we in‑
vestigated the influence of various temperatures used 
on the ability of single‑dose oxaliplatin to induce cold 
allodynia in CD‑1 mice, and we also assessed the effec‑
tiveness of amitriptyline to reduce oxaliplatin‑induced 
cold allodynia in mice. As mentioned above, recent 
studies have indicated that neuropathic pain caused 
by oxaliplatin might be related to the accumulation 
of its toxic metabolite (oxalate), which binds to volt‑
age‑gated sodium channels (Nav), and may be particu‑
larly responsible for cold allodynia effects (Ewertz et 
al. 2015, Sakurai et al. 2009). Amitriptyline is a tricyclic 
antidepressant drug with well‑documented Nav‑inhibi‑
tory properties (Horishita et al. 2017). Thus, we inves‑
tigated if the use of amitriptyline in CIPN‑related pain 
caused by oxaliplatin might be a potential treatment 
option for this condition. Previous studies have shown 
that amitriptyline reduced tactile allodynia in several 
other neuropathic pain types (Kremer et al. 2016, San‑
na et al. 2017, Sawynok and Zinger 2016), but there are 
conflicting data regarding its effect on cold allodynia, 
particularly in patients treated with platinum deriva‑
tives (Ewertz et al. 2015, Sada et al. 2012).
METHODS
Animals and housing conditions
Behavioral experiments were carried out at the De‑
partment of Pharmacodynamics, Faculty of Pharmacy, 
Jagiellonian University Medical College in Krakow, Po‑
land. Adult male albino Swiss (CD‑1) mice weighing be‑
tween 18 g and 22 g were used in the experiments. Pri‑
or to experiments the animals were kept in groups of 
10 mice in home cages at room temperature (22±2oC), un‑
der a (12:12) light/dark cycle. Before the assays the mice 
had free access to food and water. The ambient tempera‑
ture of the experimental room and the humidity (55±5%) 
were kept consistent throughout the tests. For behav‑
ioral experiments the animals were selected randomly. 
Each group consisted of 6‑10 animals. The experiments 
were performed between 8 AM and 2 PM. Immediately 
after the assay, the animals were euthanized by cervical 
dislocation. All procedures were approved by the Local 
Ethics Committee of the Jagiellonian University in Kra‑
kow (4/2016) and the treatment of animals was in full ac‑
cordance with ethical standards laid down in respective 
Polish and EU regulations (Directive No. 86/609/EEC). 
Chemicals
To induce CIPN, oxaliplatin (Tocris Bioscience, Germa‑
ny) prepared in 5% glucose solution (Polfa Kutno, Poland) 
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was administered intraperitoneally as a single dose of 
10 mg/kg. Amitriptyline was purchased from Sigma Al‑
drich (Poland). In order to assess its effect on cold allo‑
dynia in neuropathic mice treated with oxaliplatin, ami‑
triptyline was dissolved in 0.9% natrium chloride solution 
(Polfa Kutno, Poland) and injected intraperitoneally at 
doses of 1, 2.5 and 10 mg/kg.
Behavioral testing
Effect of oxaliplatin on cold allodynia (cold plate test)
The ability of oxaliplatin to induce cold allodynia was 
assessed in the cold plate test. This test was performed 
using the cold plate apparatus (hot/cold plate, Bioseb, 
France) set at three distinct temperatures of the cold plate: 
1°C, 2.5°C and 4°C. To assess how oxaliplatin affects the 
cold nociceptive threshold of mice exposed to these vari‑
ous temperatures, the mice were divided into separate ex‑
perimental groups that were tested 2 h, 3 h, 4 h and 6 h 
after oxaliplatin injection (assessment of acute‑phase cold 
allodynia). Each of these groups was subjected to the cold 
plate assay again 24 h, 72 h and finally 7 days later to estab‑
lish the impact of oxaliplatin on late‑phase cold allodynia 
(Fig. 1A).
Effect of amitriptyline on cold allodynia in oxaliplatin‑treated 
mice
Antiallodynic properties of amitriptyline in the ear‑
ly‑phase of cold allodynia (i.e., on the day of oxaliplatin 
administration) and in the late phase of oxaliplatin‑in‑
duced cold allodynia (i.e., 7 days after oxaliplatin injection; 
Fig. 1B) were assessed at one temperature set‑point chosen 
based on the results obtained in the previous experiment.
In order to measure the effects of oxaliplatin and am‑
itriptyline in the cold plate test, the animals were first 
tested to obtain baseline latencies to pain reaction be‑
fore oxaliplatin injection (referred to as ‘0 h’, ‘before ox‑
Fig. 1. Experimental protocol used to assess the impact of oxaliplatin on cold allodynia (A) and to assess antiallodynic properties of amitriptyline (B) in the 
cold plate test at 1°C, 2.5°C and 4°C. Abbreviations: AMI – amitriptyline, CPT – cold plate test, OXA – oxaliplatin.
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aliplatin latencies’). Then, oxaliplatin was injected and 
latencies to pain reaction (i.e., lifting, biting, shaking of 
hind paws, jumping, and movement deficits) were mea‑
sured again at specific time‑points (‘pre‑drug latencies’). 
Next, amitriptyline was administered and 60 min later 
post‑drug latencies to pain reaction were collected. In 
this assay, a cut‑off time of 60 s was established to avoid 
potential paw tissue damage and animals not respond‑
ing within 60 s were removed from the apparatus and 
assigned a score of 60 s.
Data analysis
Analysis of the results was performed using GraphPad 
Prism software (v.5.0, CA, USA). Numerical results are ex‑
pressed as the mean ± SEM. Statistical analysis was car‑
ried out by using one‑way analysis of variance (ANOVA), 
followed by Dunnett’s or Tukey’s post‑hoc comparisons. 
P<0.05 was considered significant.
RESULTS
Effect of oxaliplatin on the development  
of cold allodynia 
In the cold plate test with the temperature set at 
1°C oxaliplatin showed an overall effect (F7,85=15.50, 
P<0.0001). As shown in Fig. 2A, 3 h after oxaliplatin ad‑
ministration a significant (P<0.001) decrease in laten‑
cy time to pain reaction was noted and this effect was 
maintained until the end of the testing period.
A temperature of 2.5°C also revealed an overall ef‑
fect of oxaliplatin on cold allodynia in mice (F7,77=21.19, 
P<0.0001). A significant (P<0.001) reduction in latency 
time to pain reaction was observed 2 h after oxaliplatin 
injection and this effect was maintained until the end of 
the testing period (Fig. 2B).
A temperature of 4°C also revealed oxaliplatin’s abili‑
ty to induce cold allodynia in mice (F7,80=21.23, P<0.0001). 
A significant (P<0.001) reduction of latency time to pain 
reaction was observed 3 h after oxaliplatin injection and 
this effect was maintained until the end of the testing 
period on day 7 (Fig. 2C).
Antiallodynic activity of amitriptyline in 
oxaliplatin‑treated mice
In the next stage of the study we assessed the ef‑
fect of amitriptyline at three different doses (1 mg/kg, 
2.5 mg/kg and 10 mg/kg) on cold nociceptive threshold 
in oxaliplatin‑treated mice. The previous results ob‑
tained for oxaliplatin showed that onset of symptoms 
of cold allodynia appeared earliest in mice exposed to 
2.5°C, thus we used this temperature for further tests 
that aimed to establish antiallodynic properties of ami‑
triptyline. We assessed the effect of amitriptyline during 
early‑phase cold allodynia 1 h after amitriptyline admin‑
istration (i.e., 4 h after oxaliplatin injection). The effect 
of this drug on late‑phase cold allodynia was established 
1 h after amitriptyline administration on day 7 after ox‑
aliplatin injection.
Analysis of variance showed a significant overall ef‑
fect of treatment (F14,135=7.676, P<0.0001). Post hoc anal‑
ysis demonstrated that oxaliplatin lowered the cold 
nociceptive threshold and caused significant (P<0.05) 
early‑phase and late‑phase cold allodynia in all groups 
tested and amitriptyline reduced cold allodynia in ox‑
Fig. 2. Development of cold allodynia induced by intraperitoneally administered oxaliplatin. Cold allodynia was measured in the mouse cold plate 
test at various temperatures and at various time‑points (shown in Fig. 1A). Results are shown as latency time to pain reaction (lifting, biting, shaking 
hind paws, jumping, movement deficits) in response to temperatures of 1°C (A), 2.5°C (B), or 4°C (C). Statistical analysis: analysis of variance (ANOVA) 
followed by Dunnett’s post hoc comparison. Significance vs. latency before oxaliplatin (0 h): ** P<0.01, *** P<0.001.
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aliplatin‑treated mice. It is noteworthy that this antial‑
lodynic activity of amitriptyline was significant only 
for doses of 2.5 and 10 mg/kg (P<0.01 and P<0.05, re‑
spectively), and this effect was observed in the early 
phase (4 h after oxaliplatin injection, i.e., 1 h after am‑
itriptyline injection), but not in the late phase (7 days 
after oxaliplatin administration) (Fig. 3).
DISCUSSION
The results of the present study demonstrated that 
oxaliplatin lowered the pain sensitivity threshold for 
cold nociception in mice and this effect was observed at 
temperatures ranging from 1°C to 4°C. We also showed 
that amitriptyline, likely due to its Nav‑blocking prop‑
erties, was able to attenuate early‑phase cold allodynia 
caused by this platinum derivative but it had no effect 
on cold allodynia in the late phase of neuropathy.
Pain threshold is a highly subjective characteristic 
for each individual, thus for its assessment, as well as 
for the establishment of efficacy of analgesic drugs, re‑
liable methods are essential. The use of oxaliplatin as 
a tool to induce neuropathic pain and to investigate the 
efficacy of analgesics is important because this anti‑tu‑
mor drug is widely used for the treatment of various 
types of carcinoma (Petrioli et al. 2008). In line with 
this, the prevalence of oxaliplatin‑induced adverse ef‑
fects, including neuropathic pain, is high (Petrioli et al. 
2008). In contrast to types of neuropathic pain other 
than those related to CIPN, e.g, diabetic neuropathic 
pain, the guidelines and algorithms for the manage‑
ment of oxaliplatin‑induced neuropathic pain are not 
clear and there are only a few drugs, e.g, duloxetine, 
(Smith et al. 2013) that have well‑established antial‑
lodynic efficacy in oxaliplatin‑treated patients. This 
necessitates the search for novel treatment options to 
alleviate oxaliplatin‑induced neuropathic pain. 
The use of oxaliplatin in experimental pharmacolo‑
gy has several advantages over other anti‑tumor drugs 
used to model neuropathic pain in animals. Firstly, un‑
like other anti‑tumor drugs such as vincristine, which 
requires repeated administrations to lower pain thresh‑
old (Gong et al. 2016), the use of oxaliplatin for pain 
studies is much more convenient as this drug is able 
to induce neuropathic pain after only a single‑dose ad‑
ministration. Secondly, in contrast to paclitaxel which 
requires the use of solubilizers (Cremophor EL, abso‑
lute ethanol) for its preparation (Parvathy and Masocha 
2015, Sałat and Filipek 2015), oxaliplatin solutions can 
easily be prepared by dissolving in a glucose solution. 
Thirdly, oxaliplatin also produces acute neuropathy 
due to an effect of the oxalate salt on axonal sodium 
channels (Sakurai et al. 2009) and this effect is not seen 
with other platinum‑complex agents or with any oth‑
er chemotherapeutic drugs (Xiao et al. 2012). Fourthly, 
as with many other drugs inducing neuropathic pain, 
oxaliplatin induces tactile allodynia, mechano‑hyper‑
algesia, but it also causes cold hypersensitivity (cold 
allodynia), which is rather unique among neuropathic 
pain‑inducing drugs. 
Since there is no effect of oxaliplatin on heat sensi‑
tivity (Xiao et al. 2012), in our study we used the cold 
plate test as a simple method to assess the development 
of thermal (cold) allodynia in mice. In the first stage of 
the present experiment we wanted to determine if all 
of the temperatures most frequently used at the pre‑
clinical stage of drug development (for mice: 1°C ‑ 4°C, 
for details please see the introduction section) could be 
used to assess cold allodynia after oxaliplatin injection. 
Since thermal methods of evaluation can be signifi‑
cantly biased by learning in mice subjected to the cold 
or hot plate tests (Czopek et al. 2016), we used separate 
groups of mice for each temperature tested to limit this 
undesirable effect. We found that the development of 
cold allodynia could be observed as early as 2 h after 
oxaliplatin administration. It should be noted that at 
this time‑point the effect was statistically significant 
Fig. 3. Effect of amitriptyline on early‑phase and late‑phase cold allody‑
nia measured in the cold plate test in oxaliplatin‑treated mice. Results 
are shown as latency time to pain reaction (lifting, biting, shaking hind 
paws, jumping, and movement deficits) in response to 2.5°C. The effect 
of amitriptyline on early‑phase cold allodynia was measured on the 
day of oxaliplatin administration (1 h after amitriptyline injection, i.e., 
4 h after oxaliplatin injection). The effect of amitriptyline on late‑phase 
cold allodynia was measured 7  days after oxaliplatin administration 
(1 h after amitriptyline injection on this day; for the detailed descrip‑
tion of the treatment protocol, please see Fig. 1B). Statistical analysis: 
analysis of variance (ANOVA), followed by Tukey’s post hoc compar‑
ison. Significance vs. latency before oxaliplatin: # P<0.05, ## P<0.01, 
### P<0.001; significance vs. pre‑drug latency: * P<0.05, ** P<0.01. 
Pre‑drug latencies are latencies collected for each animal 3 h or 7 days 
after oxaliplatin injection but before amitriptyline administration. 
Post‑drug latencies are latencies collected for each oxaliplatin‑treated 
animal 1 h after amitriptyline administration. Abbreviations: AMI – am‑
itriptyline, OXA – oxaliplatin. 
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only in mice tested at 2.5°C. For all temperatures test‑
ed, early‑phase cold allodynia was fully developed 3 h 
after oxaliplatin injection, thus this time‑point was 
chosen for further experiments that involved measure‑
ments of pre‑drug latencies to pain reaction. 
A temperature of 2.5°C was used to assess potential 
antiallodynic properties of amitriptyline. In our pres‑
ent research this was the lowest temperature that had 
almost no effect on the pain sensitivity threshold of 
non‑neuropathic mice. For this temperature, the mean 
latency time to pain reaction of mice before oxalipla‑
tin injection was very close to the cut‑off time in this 
assay, which clearly showed that at this temperature 
cold allodynia (i.e., pain response following normally 
non‑painful thermal stimulation) could be assessed.
In our study oxaliplatin injection significantly re‑
duced latency time to pain reaction in response to 
cold stimulation. Amitriptyline partially and dose‑de‑
pendently reversed cold allodynia in neuropathic, ox‑
aliplatin‑treated mice. It is noteworthy that this effect 
was statistically significant only in the early phase and 
was noted only for doses of 2.5 mg/kg and 10 mg/kg. 
The antiallodynic effect of amitriptyline observed only 
in early‑phase cold allodynia caused by oxaliplatin 
might suggest that Nav protein expression underlies 
the development of cold allodynia in the early phase, 
but these channels are rather unlikely to play a key 
role in late‑phase cold allodynia. As mentioned above, 
several recent studies have shown that early‑phase 
cold allodynia after oxaliplatin administration can be 
attributed to the accumulation of its metabolite, oxa‑
late, which acts by binding to axonal Nav channels (Ew‑
ertz et al. 2015, Sakurai et al. 2009). Therefore, it seems 
plausible that in the early phase of neuropathy, after 
oxaliplatin administration, amitriptyline can compete 
with oxalate for binding to Nav channels. Antiallodynic 
properties of amitriptyline were also investigated pre‑
viously (Sada et al. 2012, Zhao et al. 2014). In a study by 
Sada et al. (2012), repeated administration of amitrip‑
tyline (5 and 10 mg/kg, oral route, once a day) reduced 
oxaliplatin‑induced mechanical allodynia but not cold 
hyperalgesia in the acetone test in rats and reversed 
oxaliplatin‑induced increases in the expression of 
NR2B protein and mRNA in rat spinal cord. Of note, in 
this study the acute effect of amitriptyline on animals’ 
pain behavior was not assessed. 
The influence of amitriptyline on rapid‑onset cold 
hypersensitivity as a main feature of the acute periph‑
eral neuropathy induced by oxaliplatin in mice was 
also investigated by Zhao and colleagues (2014). In 
this experiment intraperitoneal amitriptyline (5 and 
10 mg/kg) had no effect on cold hypersensitivity and 
the authors suggested that analgesics that directly sup‑
press sensory neuron hyperexcitability (e.g, pregabalin, 
mexiletine) may be more efficacious than those which 
activate the descending pain inhibitory pathways (e.g, 
amitriptyline and opioids). Our results are not in line 
with those obtained in this study. A possible explana‑
tion for this difference is that these authors used a dis‑
tinct mouse strain (C57BL/6J) and they assessed cold 
allodynia 2 h after oxaliplatin injection using the cold 
plate apparatus set at 5°C. 
In conclusion, the present experiment confirmed 
that oxaliplatin is a potent inductor of cold hypersen‑
sitivity and is able to induce cold allodynia that can 
be detected at a relatively wide range of temperatures 
(1°C–4°C) that are not harmful to untreated, non‑neu‑
ropathic subjects. Although various temperature rang‑
es and different time‑points of testing are being used in 
laboratories worldwide, in our study a rapid‑onset cold 
allodynia in oxaliplatin‑treated mice was shown for all 
temperatures tested. This effect was noted first 2 h af‑
ter oxaliplatin injection for the temperature of 2.5°C. 
The present study also provides evidence for a poten‑
tially efficacious treatment for cold‑triggered acute 
peripheral neuropathy induced by oxaliplatin with the 
use of amitriptyline. Amitriptyline at doses 2.5 and 
10 mg/kg partially reversed early‑phase cold allodynia 
caused by oxaliplatin but it was not effective in the late 
phase of neuropathy.
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